Today's Information |
Provided by: PharmaEssentia Corp. | |||||
SEQ_NO | 2 | Date of announcement | 2022/01/22 | Time of announcement | 20:40:39 |
Subject | Status update as to the Company��s patents | ||||
Date of events | 2022/01/21 | To which item it meets | paragraph 53 | ||
Statement | 1.Date of occurrence of the event:2022/01/21 2.Company name:PharmaEssentia Corp. 3.Relationship to the Company (please enter ��head office�� or ��subsidiaries��):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: On January 21, 2022, the Company��s Swiss counsel informed the Company that the Swiss Supervisory Authority made the decision to overrule AOP��s attachment/debt related applications upon the Company��s Swiss patents due to severe procedural flaws, and its relevant notifications not being properly served (the ��Decision��). For this Decision, AOP has ten days to appeal to the Swiss Federal Supreme Court; whether there will be such appeal is currently unknown. The Company herein further declares, as shown by the foregoing described Swiss Decision, previous news articles that claimed the Company��s patents were already subject to Swiss judicial auction, are actually obvious, serious misunderstandings and errors. 6.Countermeasures: The Company has appointed attorneys to keep monitoring the global status of the Company's patents, and is ready to respond to AOP��s possible subsequent actions. 7.Any other matters that need to be specified: It takes a considerable time and expenses to develop a new drug. In addition, the success of such development cannot be guaranteed. Therefore, the investors will bear investment risk and should carefully consider investment decisions. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
PharmaEssentia Corporation published this content on 22 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 January 2022 12:53:01 UTC.